DuraLock-C Catheter Lock Solution

Catheter-Related Infections Clinical Trial

Official title:

A Multicenter, Open-Label Study to Evaluate the Safety and Performance of DuraLock-C 4.0%, 30.0%, and 46.7% for the Maintenance of Central Venous Catheter Patency in Adult Hemodialysis Subjects Treated in Clinic

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04787926
• Other study ID #: 003
• Status: Terminated
• Start date: September 23, 2021
• Est. completion date: June 1, 2023

Study information

• Verified date: January 2024
• Source: Medical Components, Inc dba MedComp
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the safety and performance of DuraLock-C 4.0%, 30.0%, and 46.7% for the maintenance of central venous catheter (CVC) patency in adult hemodialysis (HD) patients

Description:

This study is a multicenter, open-label, post-market study to evaluate the safety and performance of DuraLock-C 4.0%, 30.0%, and 46.7% in the maintenance of catheter patency of an indwelling HD CVC in adult HD patients treated in clinic. On Day 0, patients to be instilled who meet all of the inclusion criteria and none of the exclusion criteria will be enrolled in the study to receive 1 of the 3 DuraLock-C solutions. It is expected that a minimum of 3 sites will enroll patients to the study in order to cover the 3 solutions to be tested; each site will enroll to 1 unique DuraLock-C solution only, until the sample size for the solution has been reached. DuraLock-C 4.0%, 30.0%, or 46.7% solutions will be instilled to lock the catheter as part of the routine care of the patient. Individual patients will receive the catheter locking solution (CLS) as a catheter lock post-HD session until catheter dysfunction is observed or until the end of the study period (Calendar Day 90). The CLSs are commercially available and will not be provided as part of the study design. End of Study (EOS) will take place at the patient's next scheduled session.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and non-pregnant females will be eligible for study entry provided that all inclusion/exclusion criteria are satisfied. Patients must fulfill all of the following inclusion criteria to be eligible for

participation in the study:

1. Able to give informed consent after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period.

2. Patients undergoing HD 3 or 4 times per week in clinic (expected to continue for the length of the study) with an established or newly placed non-tunneled or tunneled HD CVC as primary vascular access.

3. Adult male or female patients, aged =18 years at the time of screening.

4. Clinically stable as judged by the treating physician and as demonstrated by stable medical history for 30 days prior to enrollment, physical examination, and laboratory testing.

5. Expected to survive for the next 6 months and the patient is likely to require the use of a CVC for at least 90 days.

6. Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at screening

Exclusion Criteria:

• 1. Patients with an arteriovenous fistula or arteriovenous graft in use at the time of the study.

2. Patients with a history of thromboembolic disease. 3. Patients with a history of HD catheter dysfunction due to thrombosis or a blood pump speed rate <300 mL/min during HD in the past 30 days.

4. Patients with uncontrolled abnormal coagulation parameters and are at additional risk for clotting or excessive bleeding.

5. Patients who received antibiotics within the last 14 days. 6. Have had an acute infection = 30 days prior to enrollment. 7. Known allergy to heparin, including HIT.

8. Patients who received thrombolytic treatment (ie, tissue plasminogen activator [tPA]) within 4 weeks of enrollment.

9. Patients using any type of antimicrobial-coated or heparin-coated catheter. 10. Have a positive serology test for human immunodeficiency virus or hepatitis infection.

11. Current requirement for systemic immunosuppression that would increase risk of infection or any form of immunosuppressive disease.

12. Patient is currently taking another medication with known systemic drug interaction with citrate or heparin.

13. Patient is anticipated to receive a renal transplant within the study period should be excluded.

14. Patients with known or suspected liver failure. 15. Are female and pregnant, lactating, or planning to become pregnant during the study period.

16. Are currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months or previous enrollment in this study.

17. Patient has a condition the investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk.

18. Patient has an active malignancy of any type, or has been diagnosed with cancer within 5 years prior to screening (excluding squamous or basal cell carcinoma of the skin).

19. Patient has a known allergy or history of significant adverse reaction to trisodium citrate or related compounds or to any of the excipients (citric acid).

20. Any clinically significant abnormal laboratory test results found during medical screening, as determined by the investigator. NOTE: A test value above or below the normal range does not necessarily indicate that the value is "clinically significant." The determination should be made by the investigator.

21. Have a history of noncompliance with HD as assessed by an investigator. 22. Have had a major cardiovascular or cerebrovascular event within 3 months of study entry.

23. Are scheduled for living-donor transplantation within the study period, plan to change to peritoneal dialysis (PD) therapy within the study period, plan to change to a home HD treatment, or plan to relocate to an area where no study center is located.

Related Conditions & MeSH terms

• Catheter-Related Infections

Intervention

Device:
• Locking Solution
The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.

Locations

Country	Name	City	State
France	Clinique HEMERA Pays de Caux, 14 .A avenue Foch	Yvetot

Sponsors (3)

Lead Sponsor	Collaborator
Medical Components, Inc dba MedComp	Syneos Health, Veeva Systems

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Catheter Patency	Catheter Flow	90 days
Secondary	CRBSI	Incidence of catheter-related bloodstream infection (CRBSI) over the course of the study	90 Days